Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

Posted: May 15, 2022 at 2:13 am

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Company ended the quarter with approximately $247 million in cash and cash equivalents.

Read the original post:
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

Related Posts